CardioDx is a molecular diagnostics firm focused on cardiovascular genomics and the commercialization of Corus CAD, a clinically validated blood test that combines age, sex and gene expression to assess the likelihood of obstructive coronary artery disease in symptomatic patients. The company announced it will use the new funds to broaden commercial use of Corus CAD and to augment research efforts to develop additional genomic tests for coronary artery disease. CardioDx processes all Corus CAD test samples at its CLIA-certified and CAP-accredited clinical laboratory in Redwood City, California. Management cited the milestone of receiving over 100,000 Corus CAD test results as evidence of clinical adoption. Corus CAD has been clinically validated in multiple studies, including PREDICT and COMPASS, and in COMPASS demonstrated higher sensitivity and negative predictive value versus myocardial perfusion imaging. The test and company have received recognition including a Wall Street Journal Technology Innovation Award, a Gold Edison Award, and inclusion in TIME's Top 10 Medical Breakthroughs. CardioDx develops genomic diagnostics for cardiovascular disease, with its core product Corus CAD—a clinically validated, sex-specific gene expression test that measures RNA levels of 23 genes. Corus CAD is commercially available in the U.S. via a patient sample kit processed at the company’s CLIA-certified Palo Alto laboratory. The company said proceeds from the financing will support commercial expansion of Corus CAD, broaden reimbursement coverage, expand its U.S. sales force, and fund continued R&D to develop additional cardiovascular genomic diagnostics. CardioDx highlighted a favorable Medicare coverage decision from Palmetto GBA, making Corus CAD a covered benefit for more than 40 million Medicare enrollees. The company cites clinical validation in multiple prospective trials (PREDICT, COMPASS, IMPACT) and prior studies showing unmet need in noninvasive risk stratification for obstructive coronary artery disease. CardioDx develops blood-based genomic diagnostics for cardiovascular disease, centered on Corus CAD, a clinically validated gene-expression test for obstructive coronary artery disease. Corus CAD measures RNA levels of 23 genes and is the first sex-specific blood test for obstructive coronary artery disease. The test is commercially available in the United States via a patient sample kit and is processed at CardioDx’s CLIA-certified Palo Alto laboratory. Corus CAD has been used to assess more than 13,000 patients and was validated in the PREDICT study published in the Annals of Internal Medicine. The company plans to use new funding to expand reimbursement coverage in the U.S. and to continue development of additional cardiovascular genomic products. CardioDx positions Corus CAD as a decision-making tool to help clinicians avoid unnecessary procedures and radiation exposure. CardioDx develops genomic tests to aid in the assessment and tailoring of care for individuals with cardiovascular diseases such as coronary artery disease, cardiac arrhythmias and heart failure. Its initial product, Corus CAD, is a clinically validated non-invasive genomic blood test that uses gene expression levels and other patient characteristics to quantify the likelihood of obstructive coronary artery disease. The company is funded by investors including Kleiner, Perkins, Caufield & Byers, TPG Biotech, Mohr Davidow Ventures, Intel Capital and Pappas Ventures. CardioDx has raised $5M as part of a Series D round from the GE Healthymagination Fund. The new capital will be used to advance and co-develop diagnostic technologies to improve the care and management of patients with cardiovascular disease.

Total raised

$158M

Funding rounds

4

Latest round

Equity

Latest activity

Dec 2014